Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.
San Raffaele Scientific Institute, Milan, Italy.
Silvia
S
Nozza
Alba
A
Bigoloni
Andrea
A
Calcagno
Laura
L
Galli
Angela Rosa
AR
Pignataro
Antonio
A
D'Avolio
Alessia
A
Carbone
Marco
M
Ripa
Stefano
S
Bonora
Adriano
A
Lazzarin
Antonella
A
Castagna
D003510:Cyclohexanes / Q000627:therapeutic use*; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D008297:Male; D000077592:Maraviroc; D008875:Middle Aged; D020125:Mutation, Missense; D011760:Pyrrolidinones / Q000627:therapeutic use*; D000068898:Raltegravir Potassium; D017211:Treatment Failure; D014230:Triazoles / Q000627:therapeutic use*; D019562:Viral Load
D003510:Cyclohexanes; D011760:Pyrrolidinones; D014230:Triazoles; D000068898:Raltegravir Potassium; D000077592:Maraviroc
multidrug resistance; raltegravir and maraviroc dosing; simplification